229 related articles for article (PubMed ID: 21493132)
1. Restless legs syndrome (RLS) augmentation associated with dopamine agonist and levodopa usage in a community sample.
Allen RP; Ondo WG; Ball E; Calloway MO; Manjunath R; Higbie RL; Lee MR; Nisbet PA
Sleep Med; 2011 May; 12(5):431-9. PubMed ID: 21493132
[TBL] [Abstract][Full Text] [Related]
2. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.
Silver N; Allen RP; Senerth J; Earley CJ
Sleep Med; 2011 May; 12(5):440-4. PubMed ID: 21239226
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with pramipexole in the treatment of restless legs syndrome.
Merlino G; Serafini A; Robiony F; Valente M; Gigli GL
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):225-35. PubMed ID: 18248314
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic treatment in idiopathic restless legs syndrome: effects on subjective sleepiness.
Kallweit U; Khatami R; Pizza F; Mathis J; Bassetti CL
Clin Neuropharmacol; 2010; 33(6):276-8. PubMed ID: 21060282
[TBL] [Abstract][Full Text] [Related]
5. The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels.
Frauscher B; Gschliesser V; Brandauer E; El-Demerdash E; Kaneider M; Rücker L; Poewe W; Högl B
Sleep Med; 2009 Jun; 10(6):611-5. PubMed ID: 19200780
[TBL] [Abstract][Full Text] [Related]
6. Compulsive habits in restless legs syndrome patients under dopaminergic treatment.
Pourcher E; Rémillard S; Cohen H
J Neurol Sci; 2010 Mar; 290(1-2):52-6. PubMed ID: 19969309
[TBL] [Abstract][Full Text] [Related]
7. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome.
Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J
Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554
[TBL] [Abstract][Full Text] [Related]
8. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
Sleep Med; 2008 Jul; 9(5):537-41. PubMed ID: 18276187
[TBL] [Abstract][Full Text] [Related]
9. Ropinirole in restless leg syndrome.
Ahmed I
Mo Med; 2002; 99(9):500-1. PubMed ID: 12462942
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of painful sensory symptoms in restless legs syndrome: experience from two clinical trials.
Hornyak M; Sohr M; Busse M;
Sleep Med; 2011 Feb; 12(2):186-9. PubMed ID: 21256799
[TBL] [Abstract][Full Text] [Related]
11. [Impulse control disorder induced by the use of dopamine agonists].
Weber WE; Nijssen PC
Ned Tijdschr Geneeskd; 2009 Jan; 153(3):80-1. PubMed ID: 19235343
[No Abstract] [Full Text] [Related]
12. Treatment of restless leg syndrome with pergolide--an open clinical trial.
Winkelmann J; Wetter TC; Stiasny K; Oertel WH; Trenkwalder C
Mov Disord; 1998 May; 13(3):566-9. PubMed ID: 9613756
[TBL] [Abstract][Full Text] [Related]
13. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
[TBL] [Abstract][Full Text] [Related]
14. Recurrence of cluster headache with pramipexole.
Ossemann M
Acta Neurol Belg; 2010 Sep; 110(3):279-80. PubMed ID: 21114140
[TBL] [Abstract][Full Text] [Related]
15. Major depression after withdrawing dopamine agonists in two patients with restless legs syndrome and impulse control disorders.
Launois C; Leu-Semenescu S; Brion A; Arnulf I
Sleep Med; 2013 Jul; 14(7):696. PubMed ID: 23714418
[No Abstract] [Full Text] [Related]
16. An exploratory retrospective evaluation of ropinirole-associated psychotic symptoms in an outpatient population treated for restless legs syndrome or Parkinson's disease.
Stoner SC; Dahmen MM; Makos M; Lea JW; Carver LJ; Rasu RS
Ann Pharmacother; 2009 Sep; 43(9):1426-32. PubMed ID: 19690226
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of restless legs syndrome with dopamine agonists.
Ondo W; Romanyshyn J; Vuong KD; Lai D
Arch Neurol; 2004 Sep; 61(9):1393-7. PubMed ID: 15364685
[TBL] [Abstract][Full Text] [Related]
18. Identification and treatment of augmentation in patients with restless legs syndrome: practical recommendations.
Geyer J; Bogan R
Postgrad Med; 2017 Sep; 129(7):667-675. PubMed ID: 28818004
[TBL] [Abstract][Full Text] [Related]
19. Validation of the Augmentation Severity Rating Scale (ASRS): a multicentric, prospective study with levodopa on restless legs syndrome.
García-Borreguero D; Kohnen R; Högl B; Ferini-Strambi L; Hadjigeorgiou GM; Hornyak M; de Weerd AW; Happe S; Stiasny-Kolster K; Gschliesser V; Egatz R; Cabrero B; Frauscher B; Trenkwalder C; Hening WA; Allen RP
Sleep Med; 2007 Aug; 8(5):455-63. PubMed ID: 17543579
[TBL] [Abstract][Full Text] [Related]
20. Restless legs syndrome: nonpharmacologic and pharmacologic treatments.
Winkelman JW; Allen RP; Tenzer P; Hening W
Geriatrics; 2007 Oct; 62(10):13-6. PubMed ID: 17922563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
